Adicet Bio (ACET) Stock Price, Quote, News & History

Comments

Adicet Bio Inc (ACET) Stock Price, Quote, News & History

ACETNASDAQ

Trade with Public

$6.76

-0.10-1.46%

At close: Apr 9, 5:00 PM EST

$6.55

-0.31-4.52%

Pre-Market: 7:11 AM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$6.76

Volume / Avg.

860.00 / 148.59K

Day Range

- - -

52 Wk Range

6.01 - 17.44

Market Cap

$62.86M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

5.95

Recent Adicet Bio Inc News

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.

Vandana Singh

What's Going On With Adicet Bio Stock Today?

Shares of Adicet Bio are trading lower after the clinical stage biotechnology company announced a one-for-16 reverse stock split.

Alex Perry

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $80 million to fund Phase 2.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-95.25M

Investing Cash Flow (TTM)

2.39M

Financing Cash Flow (TTM)

75.25M

Free Cash Flow (TTM)

-96.98M

Capital Expenditure (TTM)

-1.74M

Net Change in Cash (TTM)

-17.61M

Analyst Trends and Forecast

Nov 25

Jan

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$78.92M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

PB Ratio (TTM)

0.41

Earnings Yield % (TTM)

-250.74%

Earnings Yield % (FWD)

-124.48%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$16.59

Company Debt

Total Debt

LT Debt

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$150.00K

Total Cash

$38.92M

Debt to Equity

0.09

Issuance of Debt (TTM)

-$150.00K

Repayment of Debt (TTM)

-$150.00K

Key Statistics

Open

$6.76

Volume / Avg.

860.00 / 148.59K

Day Range

- - -

52 Wk Range

6.01 - 17.44

Market Cap

$62.86M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

5.95

About

Sector

Health Care

Industry

Biotechnology

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Adicet Bio (ACET) stock?

You can purchase shares of Adicet Bio (NASDAQ:ACET) through any online brokerage.

View our list of the best stock brokerages

Who are Adicet Bio (ACET) competitors?

There are no as such competitors for Adicet Bio.

What is the forecast, or price target, for Adicet Bio (ACET) stock?

Adicet Bio has a consensus price target of $22.67.

What is the current price for Adicet Bio (ACET)?

The stock price for Adicet Bio (NASDAQ: ACET) is $6.55 last updated April 13, 2026 at 5:11 AM EDT.

Does Adicet Bio (ACET) pay a dividend?

There are no upcoming dividends for Adicet Bio.

When is Adicet Bio (NASDAQ:ACET) reporting earnings?

Adicet Bio does not have any upcoming earnings scheduled.

Is Adicet Bio (ACET) going to split?

There is no upcoming split for Adicet Bio.

What sector and industry does Adicet Bio (ACET) operate in?

Adicet Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Key Statistics

Open

$6.76

Volume / Avg.

860.00 / 148.59K

Day Range

- - -

52 Wk Range

6.01 - 17.44

Market Cap

$62.86M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

5.95

Recent Adicet Bio Inc News

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.

Vandana Singh

What's Going On With Adicet Bio Stock Today?

Shares of Adicet Bio are trading lower after the clinical stage biotechnology company announced a one-for-16 reverse stock split.

Alex Perry

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $80 million to fund Phase 2.

Vandana Singh